Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Neuberg received her ScD in Biostatistics from Harvard School of Public Health in 1988. She became a biostatistician at DFCI in 1987. She serves as the senior statistician for the Leukemia, Lymphoma, and Benign Hematology Programs at DFCI. She is also very involved in mentoring and teaching clinical and laboratory investigators.
Analysis of clinical trials with correlative laboratory data
Analysis of laboratory and animal data
There exists a substantial statistical literature exists on the design and analysis of clinical trials with response or time-to-event end points. However, early-stage trials with biologic end points, such as vaccine studies or investigations of targeted therapies, require alternative approaches. It is crucial that in the planning stage, the unique aspects of a biologic or molecular therapy be taken into account. This principle extends to the design of laboratory studies, and especially to those correlative laboratory studies that embedded in clinical investigations.An aspect of the complexity of laboratory studies—whether in basic science, animals, or humans--is the abundance of data. With the advent of whole genome or whole exome sequencing in conjunction with epigenetic or proteomic studies on the same patient, the number of laboratory values collected far exceeds the number of patients. Dr. Neuberg's current interests concern the planning and analysis of studies that integrate laboratory outcomes at the genome, transcriptome, or proteome level with clinical and demographic information.
Dana-Farber Cancer Institute450 Brookline AvenueCLSB 11004Boston, MA 02215Get Directions